Neoantigens in precision cancer immunotherapy: from identification to clinical applications
10.1097/CM9.0000000000002181
- VernacularTitle:Neoantigens in precision cancer immunotherapy: from identification to clinical applications
- Author:
Qiao ZHANG
1
;
Qingzhu JIA
;
Jing ZHANG
;
Bo ZHU
Author Information
1. Institute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing 400037, China
- Keywords:
Precision cancer immunotherapy;
Neoantigen;
Anti-tumor immunity;
T cells;
Vaccination
- From:
Chinese Medical Journal
2022;135(11):1285-1298
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapies targeting cancer neoantigens are safe, effective, and precise. Neoantigens can be identified mainly by genomic techniques such as next-generation sequencing and high-throughput single-cell sequencing; proteomic techniques such as mass spectrometry; and bioinformatics tools based on high-throughput sequencing data, mass spectrometry data, and biological databases. Neoantigen-related therapies are widely used in clinical practice and include neoantigen vaccines, neoantigen-specific CD8+ and CD4+ T cells, and neoantigen-pulsed dendritic cells. In addition, neoantigens can be used as biomarkers to assess immunotherapy response, resistance, and prognosis. Therapies based on neoantigens are an important and promising branch of cancer immunotherapy. Unremitting efforts are needed to unravel the comprehensive role of neoantigens in anti-tumor immunity and to extend their clinical application. This review aimed to summarize the progress in neoantigen research and to discuss its opportunities and challenges in precision cancer immunotherapy.
